Efficacy of postoperative intraperitoneal hyperthermic perfusion chemotherapy with oxaliplatin+5-Fluorouracil in the treatment of gastric cancer patients with peritoneal carcinomatosis

被引:0
|
作者
Yan, Kangpeng [1 ]
Wu, Kun [1 ]
Yan, Lan [2 ]
Liang, Lei [3 ]
Yuan, Yujun [4 ]
机构
[1] Jiangxi Canc Hosp, Abdominal Surg Oncol Ward 1, 159 Beijing East Rd, Nanchang 330029, Jiangxi, Peoples R China
[2] Jiangxi Canc Hosp, Dept Radiol, Nanchang, Jiangxi, Peoples R China
[3] Tangshan Peoples Hosp, Dept Gastroenter Surg, Tangshan, Peoples R China
[4] Quannan Peoples Hosp Jiangxi Prov, Dept Gen Surg, Ganzhou, Peoples R China
来源
JOURNAL OF BUON | 2019年 / 24卷 / 04期
关键词
gastric cancer; peritoneal carcinomatosis; oxaliplatin; 5-fluorouracil; intraperitoneal hyperthermic perfusion chemotherapy; CYTOREDUCTIVE SURGERY; SURVIVAL; TUMORS; HIPEC;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the effect of palliative laparoscopic resection of gastric cancer combined with intraperitoneal hyperthermic perfusion chemotherapy (IHPC) with oxaliplatin + 5-fluorouracil (5-FU) on gastric cancer patients with peritoneal carcinomatosis (PC). Methods: 90 patients definitely diagnosed with gastric adenocarcinoma and PC and admitted to our hospital from March 2013 to March 2016 were collected and divided into IHPC group (n=45) and control group (n=45). In IHPC group, IHPC with oxaliplatin + 5-FU was carried out for the first time on the first day after operation, and then it was conducted once every other day for a total of 4 times. The clinical efficacy, quality of life, adverse reactions, postoperative tumor recurrence and survival of the patients were observed and recorded. Results: The total effective rates in IHPC group and control group were 62.2% (28/45) and 55.6% (25/45), respectively (p>0.05). In both groups, the curative effect was the best in moderately differentiated adenocarcinoma and worst in signet ring cell carcinoma. Besides, the effective rates of Karnofsky performance status (KPS) in the two groups after operation were 82.2% (37/45) and 75.6% (34/45), respectively (p=0.606). However, the renal function indexes, serum creatinine (sCr) and blood urea nitrogen (BUN) in the two groups of patients after operation were increased, and those in the IHPC group were higher than those in the control group (p=0.016, p=0.010). Moreover, follow-up results of patients' survival revealed that the OS and PFS in the IHPC group were significantly higher than those in the control group (p=0.041, p=0.045). Conclusions: Palliative laparoscopic resection of gastric cancer combined with IHPC with oxaliplatin + 5-FU has a definite therapeutic effect on gastric cancer with PC, which can achieve a better short-term clinical therapeutic effect and better postoperative quality of life
引用
收藏
页码:1587 / 1594
页数:8
相关论文
共 50 条
  • [1] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis
    Ellison, Lynne M.
    Man, Yangao
    Stojadinovic, Alexander
    Xin, Hongwu
    Avital, Itzhak
    CHINESE JOURNAL OF CANCER RESEARCH, 2017, 29 (01) : 86 - 92
  • [2] Hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis arising from gastric cancer
    Cotte, E.
    Gilly, F. -N.
    Beaujard, A. -C.
    Glehen, O.
    CANCER RADIOTHERAPIE, 2008, 12 (6-7): : 653 - 658
  • [3] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis
    Lynne M.Ellison
    Yangao Man
    Alexander Stojadinovic
    Hongwu Xin
    Itzhak Avital
    ChineseJournalofCancerResearch, 2017, 29 (01) : 86 - 92
  • [4] Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin as a Treatment for Peritoneal Carcinomatosis Arising from the Appendix
    Marcotte, E.
    Drolet, P.
    Dube, P.
    Mitchell, A.
    Leblanc, G.
    Leclerc, Y. E.
    Frenette, S.
    Sideris, L.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S103 - S103
  • [5] Intraperitoneal hyperthermic chemotherapy as treatment of peritoneal carcinomatosis of colorectal cancer
    Markman, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1527 - 1527
  • [6] Treatment of peritoneal carcinomatosis with hyperthermic intraperitoneal chemotherapy in colorectal cancer
    Behrenbruch, Corina
    Hollande, Frederic
    Thomson, Benjamin
    Michael, Michael
    Warrier, Satish K.
    Lynch, Craig
    Heriot, Alexander
    ANZ JOURNAL OF SURGERY, 2017, 87 (09) : 665 - 670
  • [7] Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer
    Ji, Zhong-He
    Peng, Kai-Wen
    Li, Yan
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 1
  • [8] Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis
    Rihuete Caro, Cristina
    Manzanedo, Israel
    Pereira, Fernando
    Carrion-Alvarez, Lucia
    Serrano, Angel
    Perez-Viejo, Estibalitz
    EJSO, 2018, 44 (11): : 1805 - 1810
  • [9] Systemic exposure of oxaliplatin and docetaxel in gastric cancer patients with peritonitis carcinomatosis treated with intraperitoneal hyperthermic chemotherapy
    Koemans, W. J.
    van der Kaaij, R. T.
    Wassenaar, E. C. E.
    Grootscholten, C.
    Boot, H.
    Boerma, D.
    Los, M.
    Imhof, O.
    Schellens, J. H. M.
    Rosing, H.
    Huitema, A. D. R.
    van Sandick, J. W.
    EJSO, 2021, 47 (02): : 486 - 489
  • [10] Outcomes of Cytoreduction and Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer
    Alhumaid, Moayad
    Sait, Salma
    Fallatah, Emad
    AlSayegh, Nasser
    Farsi, Ali
    Nassif, Mohammed
    Farsi, Nada J.
    Akeel, Nouf
    Samkari, Ali
    Shabkah, Alaa A.
    Trabulsi, Nora
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)